Maxim Group analyst Naureen Quibria reiterated a Buy rating on Fennec Pharmaceuticals (FENC – Research Report) yesterday and set a price target of $12.00. The company’s shares closed last Tuesday at $6.97.
Quibria has an average return of 5.9% when recommending Fennec Pharmaceuticals.
According to TipRanks.com, Quibria is ranked #2258 out of 7583 analysts.
Currently, the analyst consensus on Fennec Pharmaceuticals is a Strong Buy with an average price target of $14.33, which is a 98.2% upside from current levels. In a report issued on June 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.
The company has a one-year high of $10.67 and a one-year low of $4.80. Currently, Fennec Pharmaceuticals has an average volume of 186.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.